A blended independent educational program designed by Springer Healthcare IME, in collaboration with the International Hypoglycaemia Study Group (IHSG), for diabetes specialists, primary care physicians, and specialist diabetes nurses involved in the treatment and management of people with diabetes.
Despite advances in treatment, hypoglycemia remains a prevalent complication of diabetes which is often overlooked. Newer insulins and technologies have the potential to reduce the risk of hypoglycemia and its complications. To achieve these benefits, they must be correctly integrated into an individualized treatment regimen, taking patient fears and choice into account.
This program aims to support clinicians in a time of rapidly changing treatment options, providing practical guidance in identifying and managing diabetic hypoglycemia.
Program Director Simon Heller introduces Diabetic hypoglycemia: recognizing the under-recognized with an overview of the educational content and interactive activities that have been specifically designed to benefit all healthcare professionals working in the treatment and management of people with diabetes, and their patients.
Professor Simon Heller
University of Sheffield, UK
Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, and Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust.
He trained in clinical diabetes at Queen’s Medical Centre, Nottingham and in research at the University of Nottingham and Washington University, St Louis, USA. He was Editor of Diabetic Medicine from 2000-2005. He is currently the National Speciality Lead in Diabetes to the NIHR Clinical Research Network and an NIHR Senior Investigator. He is a former member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and chairs the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee.
He chairs the International Hypoglycaemia Study group, an independently funded group of international experts with research and clinical expertise in hypoglycaemia. The group has a remit to reduce the burden of hypoglycemia though educational activities.
He chaired the glucose control group of the ADVANCE trial, is a steering committee member of the EXAMINE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps.
His research interests include the pathophysiological responses to hypoglycemia and hypoglycemia unawareness, the potential contribution and mechanisms of hypoglycemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycemia. He also conducts research concerned with developing programs (including the DAFNE intervention) to encourage more effective diabetes self-management. He has authored over 200 original research articles and reviews.
Full disclosure information
- Advisory Board Member: Eli Lilly, Novo Nordisk, Sanofi Aventis, Takeda, Zealand Pharma, UN-EEG, Boehringer Ingelheim
- Consultant: Eli Lilly, Novo Nordisk
- Speaker’s Bureau: Eli Lilly, Novo Nordisk
Compare trial data from around the World as regional experts discuss the global burden of hypoglycemia.
Guided by diabetes specialists, choose and explore different treatment paths by introducing new insulins and technologies.
Faculty: Professor Timothy Jones (Australia), Dr Emma Wilmot (UK)
Test yourself with three expert-authored case studies involving patients presenting with hypoglycemia complications. What treatment advice would you give them?
Faculty: Professor Kamlesh Khunti (UK), Dr Yingying Luo (China), Professor Ulrik Pedersen-Bjergaard (Denmark)
Watch hypothetical patient–doctor consultations covering patient fears and how to manage them. Learn with practical advice given by clinicians as they offer commentary and insights throughout the workshop.
Faculty: Professor Stephanie Amiel (UK), Professor Simon Heller (UK), Dr Emma Wilmot (UK)
Upon completion of the educational activities in this series, learners will be able to:
- Describe the latest real-world data on the prevalence of hypoglycemia and its impact on patients worldwide
- Appraise novel insulin therapies and technologies, including how to integrate them into clinical practice to improve glucose control and reduce the risk of hypoglycemia and its complications
- Debate the psychological consequences of hypoglycemia on the patient and the self-management strategies that can overcome these
Continuing Medical Education
In support of improving patient care, this activity has been planned and implemented by North American Center for Continuing Medical Education (NACCME) in joint providership with Springer Healthcare IME.
NACCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NACCME designates AMA PRA Category Credit(s)™ for the following activities:
Completion of each case study: AMA PRA Category 0.25 Credits™
Completion of each workshop: AMA PRA Category 0.5 Credits™
How To Claim Your Credits
To claim your credits for participating in the accredited activities, you will need to complete the activity then fill out the short evaluation form at the end of each module.
During completion of the evaluation form, you can select the box that indicates accreditation is required.
Use of Proprietary Names
This continuing medical education activity may include device or medicine brand names for participant clarity purposes only, due to the presence of different branded versions of the same product. No product promotion or recommendation should be inferred.
Unapproved and/or Investigational Uses of Drugs and Devices
This activity may contain information about experimental and other uses of drugs or devices that are not currently approved by the European Medicines Agency (EMA) of the European Union or the Food and Drug Administration (FDA) of the United States. Participants are strongly encouraged to consult approved product labeling for any drug or device mentioned in this activity before use. The opinions expressed during this activity are the opinions of the respective authors, presenters or moderators and do not necessarily reflect the opinions of NACCME.
The material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.
Neither NACCME nor any of its subsidiaries or affiliates is affiliated with, or formally endorsed by a medical society.
The opinions expressed in this educational activity are those of the faculty and are not attributable to NACCME or HMP. Clinical judgment must guide each professional in weighing the benefits of treatment against the risk of toxicity. Dosages, indications, and methods of use for products referred to in this activity are not necessarily the same as indicated in the package insert for each product, may reflect the clinical experience of the presenters, and may be derived from the professional literature or other clinical sources. Consult complete prescribing information before administering.
Disclosure of Relevant Financial Relationships
NACCME, LLC is an independent provider(s) of continuing medical education. NACCME, LLC has no proprietary or financial interest in medical or healthcare products over which the FDA (USA) or EMA (EU) has regulatory authority.
NACCME, LLC assures that all educational materials are reviewed to ensure for the absence of commercial bias, fair balance, scientific objectivity, and levels of evidence. The educational activity will not be influenced by commercial organizations and will not conflict with any other scheduled educational activities.
NACCME requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COIs are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.
In addition to the speaker faculty, NACCME and Springer Healthcare IME planners and staff include Chris Bolwell, Jennifer Ilcyn, Jules Morgan, and Rebecca Cox.
Chris Bolwell is a shareholder of GlaxoSmithKline. GlaxoSmithKline is not supporting this activity, nor does any content relate to their product/service.
Jennifer Ilcyn, Jules Morgan, and Rebecca Cox have no financial relationships to disclose.
North American Center for Continuing Medical Education (NACCME) complies with the legal requirements of the Americans with Disabilities Act and the rules and regulations thereof.
NACCME protects the privacy of personal and other information regarding participants, educational partners, and joint providers. NACCME and its joint providers will not release personally identifiable information to a third party without the individual’s consent, except such information as is required for reporting purposes to the appropriate accrediting agency. NACCME maintains physical, electronic, and procedural safeguards that comply with federal regulations to guard your nonpublic personal information.
Copyright © 2020 Springer Healthcare IME. All rights reserved. No part of this accredited continuing education activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from Springer Healthcare IME.
This independent resource is brought to you in collaboration with the International Hypoglycaemia Study Group (IHSG).